| 0 (0%) | 09-27 09:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 233.73 | 1-year : | 243.13 |
| Resists | First : | 200.11 | Second : | 208.16 |
| Pivot price | 196.91 |
|||
| Supports | First : | 187.11 | Second : | 155.67 |
| MAs | MA(5) : | 193.08 |
MA(20) : | 197.56 |
| MA(100) : | 178.91  |
MA(250) : | 155.6 |
|
| MACD | MACD : | 0.4 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 20.9 |
D(3) : | 25.9 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 208.16 | Low : | 118.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ASND ] has closed above bottom band by 18.3%. Bollinger Bands are 18.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 192.47 - 193.74 | 193.74 - 194.89 |
| Low: | 185.36 - 187.01 | 187.01 - 188.49 |
| Close: | 189.46 - 192.04 | 192.04 - 194.38 |
Fri, 26 Sep 2025
(ASND) Investment Strategy and Analysis (ASND:CA) - news.stocktradersdaily.com
Wed, 24 Sep 2025
Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND) - Yahoo Finance
Tue, 23 Sep 2025
Leerink Partners Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $225 - 富途牛牛
Sun, 14 Sep 2025
Ascendis Pharma A/S $ASND Shares Sold by Zimmer Partners LP - MarketBeat
Tue, 02 Sep 2025
New Analyst Forecast: $ASND Given $230.0 Price Target - Quiver Quantitative
Thu, 21 Aug 2025
Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 61 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 107 (%) |
| Shares Short | 2,680 (K) |
| Shares Short P.Month | 2,760 (K) |
| EPS | -5.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.1 |
| Profit Margin | -55.3 % |
| Operating Margin | -33.5 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 339 % |
| Gross Profit (p.s.) | 6.87 |
| Sales Per Share | 8.1 |
| EBITDA (p.s.) | -4.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -165 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -35.82 |
| PEG Ratio | 0 |
| Price to Book value | -61.94 |
| Price to Sales | 23.68 |
| Price to Cash Flow | -70.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|